BIOMAT Database Logo BIOMAT Database Logo

Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist. 1990

H Tsunoda, and Y Sakuma, and K Harada, and K Muramoto, and S Katayama, and T Horie, and N Shimomura, and R Clark, and S Miyazawa, and K Okano
Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan.

(S)-(+)-6-(2-Chlorophenyl)-3-cyclopropanecarbonyl-8,11- dimethyl - 2,3,4,5 - tetrahydro - 8H - pyrido[4',3':4,5] thieno[3,2-fl-[1,2,4]triazolo]4,3-a][1,4]diazepine (E-6123) is a newly synthesized platelet-activating factor (PAF) antagonist. The effects of E-6123 on in vitro and in vivo PAF-induced responses were investigated. The IC50 values of E-6123 on 3H-PAF binding to human and guinea pig platelets were 2.7 and 3.0 nmol/l, respectively, and those on PAF-induced platelet aggregation in platelet-rich plasma of human, guinea pig and beagle dog were 10.1, 14.7 and 16 nmol/l, respectively. Oral administration of E-6123 at 3 and 10 micrograms/kg to dogs inhibited ex vivo PAF-induced platelet aggregation in a dose-dependent manner. In guinea pigs, E-6123 at 3 micrograms/kg completely inhibited ex vivo PAF-induced platelet aggregation up to 8 h and the inhibition was still significant at 24 h after administration. Occupancy of the platelet PAF receptor by E-6123 at 3 h and 24 h after administration amounted to 80% and 56%, respectively. Bronchoconstriction induced by PAF injection in guinea pigs was inhibited dose-dependently by oral or intravenous administration of E-6123 at similar doses. The IC50 value of E-6123 at 3 h after oral administration was 1 microgram/kg. Oral administration of E-6123 at 3 micrograms/kg inhibited the bronchoconstriction by more than 90% up to 8 h. Hemato-concentration induced by PAF injection in guinea pigs was inhibited by oral administration of E-6123 at 10 micrograms/kg. E-6123 also protected mice from PAF injection-induced death in a dose-dependent manner.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008813 Mice, Inbred ICR An inbred strain of mouse that is used as a general purpose research strain, for therapeutic drug testing, and for the genetic analysis of CARCINOGEN-induced COLON CANCER. Mice, Inbred ICRC,Mice, ICR,Mouse, ICR,Mouse, Inbred ICR,Mouse, Inbred ICRC,ICR Mice,ICR Mice, Inbred,ICR Mouse,ICR Mouse, Inbred,ICRC Mice, Inbred,ICRC Mouse, Inbred,Inbred ICR Mice,Inbred ICR Mouse,Inbred ICRC Mice,Inbred ICRC Mouse
D010972 Platelet Activating Factor A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION. AGEPC,Acetyl Glyceryl Ether Phosphorylcholine,PAF-Acether,Phosphorylcholine, Acetyl Glyceryl Ether,1-Alkyl-2-acetyl-sn-glycerophosphocholine,Platelet Aggregating Factor,Platelet Aggregation Enhancing Factor,Platelet-Activating Substance,Thrombocyte Aggregating Activity,1 Alkyl 2 acetyl sn glycerophosphocholine,Aggregating Factor, Platelet,Factor, Platelet Activating,PAF Acether,Platelet Activating Substance
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D010975 Platelet Aggregation Inhibitors Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. Antiaggregants, Platelet,Antiplatelet Agent,Antiplatelet Agents,Antiplatelet Drug,Blood Platelet Aggregation Inhibitor,Blood Platelet Antagonist,Blood Platelet Antiaggregant,PAR-1 Antagonists,Platelet Aggregation Inhibitor,Platelet Antagonist,Platelet Antagonists,Platelet Antiaggregant,Platelet Antiaggregants,Platelet Inhibitor,Protease-Activated Receptor-1 Antagonists,Antiplatelet Drugs,Blood Platelet Aggregation Inhibitors,Blood Platelet Antagonists,Blood Platelet Antiaggregants,Platelet Inhibitors,Agent, Antiplatelet,Aggregation Inhibitor, Platelet,Antagonist, Blood Platelet,Antagonist, Platelet,Antiaggregant, Blood Platelet,Antiaggregant, Platelet,Drug, Antiplatelet,Inhibitor, Platelet,Inhibitor, Platelet Aggregation,PAR 1 Antagonists,Platelet Antagonist, Blood,Platelet Antiaggregant, Blood,Protease Activated Receptor 1 Antagonists
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

H Tsunoda, and Y Sakuma, and K Harada, and K Muramoto, and S Katayama, and T Horie, and N Shimomura, and R Clark, and S Miyazawa, and K Okano
Interspecies scaling of a thienodiazepine platelet-activating factor receptor antagonist.
July 1995, Drug metabolism and disposition: the biological fate of chemicals,
H Tsunoda, and Y Sakuma, and K Harada, and K Muramoto, and S Katayama, and T Horie, and N Shimomura, and R Clark, and S Miyazawa, and K Okano
Dual effects of a novel thienodiazepine platelet-activating factor antagonist, on drug-oxidizing enzymes in beagle dog.
April 1994, Xenobiotica; the fate of foreign compounds in biological systems,
H Tsunoda, and Y Sakuma, and K Harada, and K Muramoto, and S Katayama, and T Horie, and N Shimomura, and R Clark, and S Miyazawa, and K Okano
Biological and pharmacological effects of pinusolide, a novel platelet activating factor antagonist.
December 1995, Planta medica,
H Tsunoda, and Y Sakuma, and K Harada, and K Muramoto, and S Katayama, and T Horie, and N Shimomura, and R Clark, and S Miyazawa, and K Okano
Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
October 1991, The Journal of pharmacology and experimental therapeutics,
H Tsunoda, and Y Sakuma, and K Harada, and K Muramoto, and S Katayama, and T Horie, and N Shimomura, and R Clark, and S Miyazawa, and K Okano
Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.
December 1991, Lipids,
H Tsunoda, and Y Sakuma, and K Harada, and K Muramoto, and S Katayama, and T Horie, and N Shimomura, and R Clark, and S Miyazawa, and K Okano
Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor.
June 1987, The Journal of pharmacology and experimental therapeutics,
H Tsunoda, and Y Sakuma, and K Harada, and K Muramoto, and S Katayama, and T Horie, and N Shimomura, and R Clark, and S Miyazawa, and K Okano
Prehispanolone, a novel platelet activating factor receptor antagonist from Leonurus heterophyllus.
July 1991, British journal of pharmacology,
H Tsunoda, and Y Sakuma, and K Harada, and K Muramoto, and S Katayama, and T Horie, and N Shimomura, and R Clark, and S Miyazawa, and K Okano
Pharmacological properties of YM264, a potent and orally active antagonist of platelet-activating factor.
January 1990, Archives internationales de pharmacodynamie et de therapie,
H Tsunoda, and Y Sakuma, and K Harada, and K Muramoto, and S Katayama, and T Horie, and N Shimomura, and R Clark, and S Miyazawa, and K Okano
Radioimmunoassay for the novel platelet activating factor receptor antagonist E5880.
May 1994, Journal of pharmaceutical sciences,
H Tsunoda, and Y Sakuma, and K Harada, and K Muramoto, and S Katayama, and T Horie, and N Shimomura, and R Clark, and S Miyazawa, and K Okano
Yangambin: a new naturally-occurring platelet-activating factor receptor antagonist: in vivo pharmacological studies.
April 1995, Planta medica,
Copied contents to your clipboard!